First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC October 28, 2026
First Patients enrolled in Standard of Care Chemo Combination Cohorts of Global Ph 1/2 ASCEND Trial of CR-001 October 28, 2026
VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Data from FURTHER Ph 1b (FURMO-002) of firmonertinib in 1L EGFR PACC-mutant NSCLC published in Cancer Cell October 20, 2026
Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the US FDA for CRC and NSCLC October 14, 2026
FAILED TRIAL: FURVENT Ph 3 trial of firmonertinib monotherapy in NSCLC patients with EGFR exon 20 insertion mutations did not meet primary PFS endpoint by BICR October 14, 2026
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of NSCLC October 6, 2026
NDA Submission Initiated for Zipalertinib + Chemo in 1L EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program October 6, 2026
Ifinatamab Deruxtecan BLA for Certain Patients with Previously Treated ES-SCLC Voluntarily Withdrawn October 1, 2026
New Analyses Reinforcing Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC Announced September 22, 2026
Ph 2 ALISCA®-Lung2 Trial of Alisertib + Paclitaxel Initiated for Patients with Advanced SCLC September 22, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 22, 2026
GX-BP1 Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination September 22, 2026
Updated Data from Ph 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of BH-30643 in EGFR C797S-Positive NSCLC Presented September 22, 2026
SYS6010 granted breakthrough therapy designation by NMPA in China for patients with actionable genomic alteration-negative non-squamous NSCLC September 22, 2026
